

Clinical Challenges and Therapeutic Strategies for Multidrug-Resistant *Mycobacterium*

Johnny Alexa*

Department of Gastroenterology, St Vincent's Hospital, Sydney, Australia

DESCRIPTION

The emergence and spread of multidrug-resistant strains of human *Mycobacterium* pose a significant threat to public health worldwide. *Mycobacterium*, a genus of bacteria, includes several species that cause various diseases in humans, with *Mycobacterium tuberculosis* being the most well-known. Over time, due to indiscriminate use of antibiotics and incomplete treatment regimens, certain strains of *Mycobacterium* have developed resistance to multiple drugs commonly used to combat them [1-3]. This multidrug resistance has become a pressing issue, hindering efforts to control and eliminate these infectious diseases. In this article, we explore the challenges posed by multidrug-resistant human *Mycobacterium* and discuss potential strategies to address this growing concern.

Multidrug resistance

Multidrug resistance occurs when bacteria, including *Mycobacterium*, develop the ability to withstand the effects of multiple antimicrobial drugs that were previously effective against them [4-6]. This resistance is primarily caused by genetic mutations in the bacteria, which enable them to survive and proliferate even in the presence of antibiotics. Over time, the selective pressure exerted by the overuse and misuse of antibiotics has favored the survival of drug-resistant strains, leading to their prevalence in many regions.

Multidrug-resistant human *Mycobacterium*

Human *Mycobacterium* species that have developed multidrug resistance, particularly *Mycobacterium tuberculosis*, are of utmost concern. Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, is a highly infectious disease that primarily affects the lungs. Multidrug-Resistant Tuberculosis (MDR-TB) is defined as resistance to at least two of the most potent first-line anti-TB drugs, isoniazid and rifampicin [7]. In more severe cases, Extensively Drug-Resistant Tuberculosis (XDR-TB) arises, indicating resistance to additional second-line drugs.

Controlling multidrug resistance

Inadequate diagnostics: Timely and accurate diagnosis of drug-resistant *Mycobacterium* infections is crucial for effective management.

However, conventional laboratory methods can be time-consuming and may not provide comprehensive drug susceptibility testing. There is a need for rapid and reliable diagnostic techniques to identify drug-resistant strains early and guide appropriate treatment.

Complex treatment regimens: Treating multidrug-resistant *Mycobacterium* infections is challenging due to limited treatment options. Second-line drugs used to combat drug-resistant strains are often less effective, more toxic, and require longer durations of treatment [8]. Moreover, treatment adherence is crucial, as incomplete or interrupted therapy can lead to the development of further resistance, making the infection even more difficult to manage.

Limited access to healthcare: Multidrug-resistant *Mycobacterium* infections are more common in low-resource settings, where access to quality healthcare and diagnostic facilities may be limited. This exacerbates the burden of drug resistance and makes it harder to control the spread of these infections [9].

Strategies of multidrug resistance

Strengthening surveillance and diagnostics: Robust surveillance systems are essential to monitor the prevalence and spread of multidrug-resistant strains. Investment in rapid and accurate diagnostic tools, such as molecular testing and whole-genome sequencing, can aid in identifying drug-resistant strains promptly. These advances in diagnostics can facilitate appropriate treatment decisions and help contain the transmission of resistant strains.

Research and development: Continued investment in research and development is crucial to identify new drugs and treatment regimens for multidrug-resistant *Mycobacterium* infections [10]. Efforts should focus on developing novel antimicrobial agents with different mechanisms of action, as well as optimizing existing drugs to enhance their effectiveness against drug-resistant strains.

CONCLUSION

The multidrug resistance of human *Mycobacterium*, particularly in the case of *Mycobacterium tuberculosis*, presents a formidable

Correspondence to: Johnny Alexa, Department of Gastroenterology, St Vincent's Hospital, Sydney, Australia, E-mail: Johnnya@gmail.com

Received: 01-May-2023, Manuscript No. MDTL-23-25119; **Editor assigned:** 03-May-2023, Pre QC No. MDTL-23-25119(PQ); **Reviewed:** 17-May-2023, QC No. MDTL-23-25119; **Revised:** 24-May-2023, Manuscript No. MDTL-23-25119(R); **Published:** 31-May-2023, DOI: 10.35248/2161-1068.23.13.357.

Citation: Alexa J (2023) Clinical Challenges and Therapeutic Strategies for Multidrug-Resistant *Mycobacterium*. *Mycobact Dis*. 13:357.

Copyright: © 2023 Alexa J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

challenge to global health. The spread of drug-resistant strains compromises the effectiveness of existing treatment regimens and threatens the progress made in controlling these infectious diseases. Addressing this issue requires a multi-faceted approach involving improved diagnostics, research and development of new drugs, and enhanced infection control measures. Timely and accurate diagnosis, coupled with the availability of effective treatment options, is crucial for successful management of drug-resistant *Mycobacterium* infections.

REFERENCES

1. Li G, Zhang J, Guo Q, Jiang Y, Wei J, Zhao LL, et al. Efflux pump gene expression in multidrug-resistant *Mycobacterium tuberculosis* clinical isolates. *PloS one*. 2015;10(2):e0119013.
2. Li QJ, Jiao WW, Yin QQ, Li YJ, Li JQ, Xu F, et al. Positive epistasis of major low-cost drug resistance mutations rpoB531-TTG and katG315-ACC depends on the phylogenetic background of *Mycobacterium tuberculosis* strains. *Int J Antimicrob Agents*. 2017;49(6):757-762.
3. Liu F, Chen J, Wang P, Li H, Zhou Y, Liu H, et al. MicroRNA-27a controls the intracellular survival of *Mycobacterium tuberculosis* by regulating calcium-associated autophagy. *Nat Commun*. 2018;9(1):4295.
4. Lugo-Villarino G, Troegeler A, Balboa L, Lastrucci C, Duval C, Mercier I, et al. The C-Type lectin receptor DC-SIGN Has an anti-inflammatory role in human M (IL-4) macrophages in response to *Mycobacterium tuberculosis*. *Front Immunol*. 2018;9:1123.
5. Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in *Mycobacterium tuberculosis*. *PloS one*. 2012;7(4):e34538.
6. Marimani M, Ahmad A, Duse A. The role of epigenetics, bacterial and host factors in progression of *Mycobacterium tuberculosis* infection. *Tuberculosis*. 2018;113:200-214.
7. McDonough KA, Kress Y. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of *Mycobacterium tuberculosis*. *Infect Immun*. 1995;63(12):4802-4811.
8. Middlebrook G, Cohn M. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. *Science*. 1953;118(3063):297-299.
9. Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant *Mycobacterium tuberculosis*. *Trends Genet*. 2013;29(3):160-169.
10. Mehaffy C, Creissen E, Troudt J, Troy A, Bielefeldt-Ohmann H, Burgos M, et al. Virulence of *Mycobacterium tuberculosis* after acquisition of isoniazid resistance: Individual nature of katG mutants and the possible role of AhpC. *PloS one*. 2016;11(11):e0166807.